SEC Filing Summary: Medasorb Technologies Corporation (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Medasorb Technologies Corporation on May 22, 2007. The report discloses a corporate governance event effective as of the filing date. Note: The registrant name in the filing is Medasorb Technologies Corporation, not Cytosorbents Corp.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of a new director to the Board of Directors.
- Event: Appointment of Martin F. Whalen to the Board of Directors.
- Effective Date: May 22, 2007.
- Background: Mr. Whalen, 66, is the President and principal of M.W. Orthopedics, Inc. He possesses over forty years of experience in hospital and surgical fields.
- Prior Service: Former Board member of Biomet Inc. (1988–1992) and Founders Bank (1987–2000).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the current corporate name and ticker symbol, as the filing lists "Medasorb Technologies Corporation" while the request metadata referenced "Cytosorbents Corp."
- Confirm the qualifications and potential conflicts of interest for the newly appointed director, Martin F. Whalen.
- Review subsequent filings for financial performance data, as this 8-K contains no financial metrics.